AWM Investment Company Inc. Sells 15,000 Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT)

AWM Investment Company Inc. decreased its holdings in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 9.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 150,000 shares of the medical instruments supplier's stock after selling 15,000 shares during the quarter. LeMaitre Vascular comprises approximately 1.7% of AWM Investment Company Inc.'s investment portfolio, making the stock its 26th biggest holding. AWM Investment Company Inc. owned about 0.67% of LeMaitre Vascular worth $13,821,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of LMAT. Barclays PLC raised its position in shares of LeMaitre Vascular by 394.5% during the 3rd quarter. Barclays PLC now owns 36,577 shares of the medical instruments supplier's stock valued at $3,396,000 after acquiring an additional 29,180 shares during the last quarter. Albion Financial Group UT grew its stake in shares of LeMaitre Vascular by 5.7% during the fourth quarter. Albion Financial Group UT now owns 3,796 shares of the medical instruments supplier's stock worth $350,000 after purchasing an additional 204 shares during the period. SG Americas Securities LLC bought a new stake in LeMaitre Vascular in the fourth quarter valued at about $158,000. Linden Thomas Advisory Services LLC increased its stake in shares of LeMaitre Vascular by 5.6% in the 4th quarter. Linden Thomas Advisory Services LLC now owns 34,482 shares of the medical instruments supplier's stock valued at $3,177,000 after acquiring an additional 1,834 shares during the last quarter. Finally, KBC Group NV raised its position in shares of LeMaitre Vascular by 58.4% in the 4th quarter. KBC Group NV now owns 1,112 shares of the medical instruments supplier's stock valued at $102,000 after acquiring an additional 410 shares during the period. 84.64% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of analysts recently commented on LMAT shares. Oppenheimer cut shares of LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research report on Friday, February 28th. Wells Fargo & Company initiated coverage on LeMaitre Vascular in a report on Thursday, February 13th. They set an "equal weight" rating and a $95.00 price objective on the stock. Lake Street Capital increased their target price on LeMaitre Vascular from $105.00 to $110.00 and gave the stock a "buy" rating in a research note on Friday, February 28th. Finally, Barrington Research lowered shares of LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research note on Friday, February 28th. Five investment analysts have rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $98.14.

LeMaitre Vascular Trading Up 2.9%

Shares of NASDAQ LMAT traded up $2.28 during midday trading on Monday, reaching $81.40. The company's stock had a trading volume of 205,755 shares, compared to its average volume of 167,047. The stock has a 50 day simple moving average of $84.19 and a 200-day simple moving average of $92.41. The stock has a market capitalization of $1.84 billion, a price-to-earnings ratio of 44.48, a PEG ratio of 2.22 and a beta of 0.86. LeMaitre Vascular, Inc. has a fifty-two week low of $71.42 and a fifty-two week high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The medical instruments supplier reported $0.48 EPS for the quarter, missing analysts' consensus estimates of $0.50 by ($0.02). The business had revenue of $59.87 million for the quarter, compared to the consensus estimate of $57.61 million. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. The company's revenue for the quarter was up 12.0% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.44 EPS. As a group, equities analysts anticipate that LeMaitre Vascular, Inc. will post 1.94 EPS for the current year.

LeMaitre Vascular Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, May 29th. Stockholders of record on Thursday, May 15th will be issued a dividend of $0.20 per share. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.98%. The ex-dividend date of this dividend is Thursday, May 15th. LeMaitre Vascular's dividend payout ratio is presently 40.40%.

Insider Activity

In other news, insider Trent G. Kamke sold 2,009 shares of the business's stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $82.12, for a total value of $164,979.08. Following the completion of the transaction, the insider now directly owns 5,564 shares in the company, valued at approximately $456,915.68. The trade was a 26.53% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO George W. Lemaitre sold 76,868 shares of the company's stock in a transaction on Monday, May 19th. The stock was sold at an average price of $85.79, for a total value of $6,594,505.72. Following the sale, the chief executive officer now owns 1,796,783 shares of the company's stock, valued at $154,146,013.57. The trade was a 4.10% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 102,009 shares of company stock valued at $8,721,836. 9.50% of the stock is owned by insiders.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.